The importance of patient sharing between hospitals on MRSA transmission

In a remarkable quirk of academic publishing, two virtually identical studies by separate research groups in the UK (one in London, and one in Cambridge) published a week apart have come to the same conclusion: that we are missing a sizable portion of MRSA transmission by focussing solely on wards in a single hospital. A referral-network level view is required for an accurate picture of MRSA transmission. (You may have seen some press about the Cambridge article, e.g. on the BBC here.)

Continue reading

Advertisements

WHO guidelines for the prevention and control of carbapenem-resistant organisms

WHO have just released some guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aerugionsa. This guideline builds on the excellent WHO core components for IPC guidelines.

Continue reading

What’s going on during World Antibiotic Awareness Week 2017

It probably won’t have escaped your attention that it’s World Antibiotic Awareness Week (#WAAW). Here’s a quick summary of what’s going on this week that may be of interest. Please feel free to add to this shared resource in the comments section.

Continue reading

ESPAUR Report 2017: two steps forward, one step back

The next iteration of the annual ESPAUR report has been published. It’s a comprehensive, epic tome (almost 200 pages, plus an online appendix if that’s not enough for you!) so, I’ve summarised a few key points here – but the whole report is well worth a read. The number of Gram-negative BSIs is increasing (and we don’t know why); overall antibiotic prescribing is down driven by GP reductions; there’s a small increase in antibiotic prescribing in hospitals overall but early success in reducing broad spectrum agents (pip/tazo and carbapenems); and the results of the national PPS are out!

Continue reading

Counting the cost of HCAI-related litigation

I heard an eye-opening talk at IPS about the cost of HCAI-related litigation to the NHS. This is something that gets talked about a lot in economic analyses (“these figures do not include the cost of litigation”), but it is difficult to find accurate figures on the scale of the expense. Data from NHS Resolution* suggests that HCAI-related litigation costs the NHS in the region of £60m per annum, which accounts for around 4% of all harm settlements from NHS Resolution each year.

Continue reading

Mutational colistin resistance in CPE is the clear and present danger, not plasmid-mediated mcr genes

There has been a lot of concern in scientific journals and the mainstream media about colistin resistance in Enterobacteriaceae caused by plasmid-mediated resistance genes (the mcr genes). However, an article published today by our group suggests that mutational colistin resistance rather than plasmid-mediated mcr genes is a more pressing clinical threat.

Continue reading